Kosh Agarwal
0000-0002-4754-828X
405 papers found
Refreshing results…
The Cost-Effectiveness of Sofosbuvir Treatment Pre-Transplant to Prevent HCV Recurrence Post-Transplant
Can expression of interferon-stimulated genes in pre-treatment liver biopsy of chronic hepatitis B patients predict therapy response and long-term HBV infection outcome?
Patients Maintained on Opioid Substitutes Undergoing Liver Transplantation: A Single Centre Experience
Serum Cystatin C and NGAL levels at the start of protease inhibitor antiviral therapy positively predict renal dysfunction development and anaemia severity
Virological Response in Treatment-Naive Patients With Chronic HCV Genotype-1 Infection Receiving Faldaprevir Plus Pegylated Interferon alpha-2A and Ribavirin Is Unaffected by Ribavirin Dose Reduction
Postoperative Confusion Following Liver Transplantation: A Multifactorial and Under Recognised Occurrence
IP-10 levels in HIV/HCV co-infection decrease with the initiation of successful antiretroviral (ART) therapy: Implications for earlier ART in co-infected patients?
Switch to the second generation of nucelos(t)ide analogues from de-novo lamivudine plus adefovir in sequentially treated chronic hepatitis B patients improves viral response and leads to sharper HBsAg decline
Faldaprevir Plus Pegylated Interferon/Ribavirin Did Not Increase Anaemia Compared With Pegylated Interferon/Ribavirin in HCV Genotype-1, Treatment-Naive Patients: Pooled Analysis of Phase III Studies
Pre-Operative Predictors of Renal Replacement Therapy after Orthotopic Liver Transplant for Chronic Liver Disease
Predicting future outcome in infancy-acquired chronic hepatitis B - importance of quantitative HBeAg and HBsAg plasma levels, HBV DNA viral load and IP10 plasma levels
British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013.
The association of pretransplant ferritin level with waiting list and post-transplant survival. Does ferritin actually predict outcome?
Faldaprevir Plus Pegylated Interferon Alfa-2a and Ribavirin in Chronic HCV Genotype-1 Treatment-Naïve Patients: Final Results from STARTVerso1: A Randomized, Double-blind, Placebo-Controlled, Phase 3 Trial
Treatment of chronic hepatitis C virus infection after liver transplantation
OPTIMIZE trial: Non-inferiority of twice-daily telaprevir versus administration every 8 hours in treatment-naïve, genotype 1 HCV infected patients
Clinical Factors That Predict Noncirrhotic Portal Hypertension in HIV-Infected Patients: A Proposed Diagnostic Algorithm
Liver abnormalities in the immunosuppressed
Maintaining clinical governance when giving telephone advice
Patient perception of skin-cancer prevention and risk after liver transplantation
Missing publications? Search for publications with a matching author name.